BrainStorm Cell Therapeutics announced that it has signed a definitive agreement with the Mayo Clinic in Rochester, Minnesota to conduct its Phase II clinical trial of NurOwn(TM) in amyotrophic lateral sclerosis (ALS), pending FDA approval. In addition, Mayo's Human Cell Therapy Laboratory will manufacture the NurOwn cells for their clinical trial participants. The other two sites slated for the multi-center trial are the University of Massachusetts Memorial Hospital and Massachusetts General Hospital.